Invention:
This technology is a 21-gene reactive oxygen species (ROS)-associated molecular signature that predicts survival in septic patients. This particular signature has outperformed randomly generated signatures of the same signature gene size. This signature is easily assayed from peripheral blood and can potentially predict.
Background:
There is a significant amount of evidence that oxidative stress plays a large role in pathogenesis of sepsis-associated multiple organ failure. Sepsis-related multiple organ dysfunction syndrome leads to a large number of deaths in intensive care units. Sepsis syndrome’s mortality rate is 26% to 82% depending on whether septic shock occurs. Currently, there are no reliable diagnostic biomarkers available to predict survival of patients with sepsis.
Applications:
- Diagnostic tool and/or service for patients with sepsis
Advantages:
- Traditional biomarkers (C-reactive protein, interleukin-6, procalcitonin) are not reliable in predicting survival
- ROS-associated biomarkers were shown to predict the odds of patient's outcome
Published Patent Application: WO2017112921A1
Related Publication: Reactive oxygen species-associated molecular signature predicts survival in patients with sepsis
Status: issued U.S. patent #11,230,735
